ArticleEsophagus : official journal of the Japan Esophageal Society2025

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as first line chemotherapy for patients with unresectable advanced esophageal cancer in Japan.

Hirohito Kakinuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.